Studies showing that hormone replacement therapy can raise the risk of heart disease, cancer and blood clots have knocked U.S. prescriptions for the drugs back to where they were nine years ago, according to a report in this week's issue of the Journal of the American Medical Association.
This suggests that doctors "may rapidly abandon well-established therapies when studies demonstrate harm" and that "patients also played a major role" in the reversal, Stanford University School of Medicine researchers noted.
The authors found that the number of hormone therapy prescriptions rose to 90 million in 1999 from 58 million in 1995 and remained stable through June 2002. Estrogen/progestin combinations, primarily Wyeth's Prempro, accounted for most of the growth.
Study findings released starting in July 2002 triggered an avalanche of bad news about the therapy, and a sharp drop in prescriptions followed.
If prescription rates seen through July 2003 continue, the report said, there were probably 57 million written last year, close to the rate in 1995.
The U.S. Food and Drug Administration recommends that post-menopausal women who take hormone therapy for hot flashes or vaginal dryness use the lowest possible dose for the shortest possible time.
SOURCE: Journal of the American Medical Association, January 7, 2003.
Ultimi Articoli
Milano — “Gente di facili costumi” al Manzoni, ritmo vivo e dialoghi che tengono la scena
Facebook Ads, perché il link diretto converte meno — il nodo delle campagne da 30.000 euro
Como accende il 2026 nel segno di Volta: un anno di eventi verso il bicentenario
Lombardia, parere negativo a due impianti agrivoltaici nel Pavese — suolo agricolo al centro della decisione regionale
Regione Lombardia stanzia 53 milioni per riqualificare 1.700 alloggi sfitti
Palazzo Lombardia celebra Diana Stanga con dieci opere dedicate alla natura
Milano — Triennale racconta l’alfabeto del design di Barber e Osgerby
Dogliani — Il Festival della TV festeggia quindici anni con i “Dialoghi Coraggiosi”
Annalisa, il tour “Ma noi siamo fuoco — Capitolo II” accende i palasport italiani fino al 16 maggio 2026